A Phase 4 interventional study of sildenafil citrate in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 10 sites in Mexico. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.
Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 24th largest by enrollment, is one of 2 that started in 2007, is one of 30 in phase 4, and was the 19th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 6 · Phase 4 30
First in 2002; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 108 across the 50 interventional studies. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
27 studies in Erectile Dysfunction by Viatris Inc.: none open now, none under way, none of them phase 3. Of 27 finished, 5 (19%) have results posted.
Among the 27 studies in Erectile Dysfunction by Viatris Inc., this one is the 16th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2007, is one of 19 in phase 4, and was the 14th registered.
Viatris Inc.’s Erectile Dysfunction studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing sildenafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 27 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter open label study to assess the efficacy of sildenafil rapid dose titration to 100 mg in men with erectile dysfunction, based on the Erectile Function (EF) domain score of the International Index of Erectile Function (IIEF) questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
Drug: sildenafil citrate
Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF)
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 \& 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Time frame: Week 6 LOCF
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score - Change From Baseline at Weeks 2, 4 and 6
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 \& 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Week 2
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 \& 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
International Index of Erectile Function (IIEF), Orgasmic Function Domain- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
International Index of Erectile Function (IIEF), Sexual Desire Domain Score- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
Time frame: Week 2, Week 4, and Week 6
International Index of Erectile Function (IIEF), Intercourse Satisfaction Domain Score- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Baseline
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
International Index of Erectile Function (IIEF), Overall Satisfaction Domain Score- Change From Week 2
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Quality of Erection Questionnaire (QEQ): Total Score - Change From Baseline
QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
Time frame: Week 2, Week 4, and Week 6
Quality of Erection Questionnaire (QEQ): Total Score- Change From Week 2
QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
Time frame: Week 4 and Week 6
Sexual Experience Questionnaire (Sex-Q): Erection Domain - Change From Baseline
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
Time frame: Week 2, Week 4 and Week 6
Sexual Experience Questionnaire (Sex-Q): Erection Domain- Change From Week 2
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Baseline
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
Time frame: Week 2, Week 4, and Week 6
Sexual Experience Questionnaire (Sex-Q): Satisfaction Domain - Change From Week 2
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
Time frame: Week 4 and Week 6
Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Baseline
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
Time frame: Week 2, Week 4, and Week 6
Sexual Experience Questionnaire (Sex-Q): Relationship Domain - Change From Week 2
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 1 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \["Were you able to insert your penis into your partner's vagina?"\] = "Yes") / (number of occasions where SEP Question 2 was answered "Yes" or "No").
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 2 on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \["Were you able to insert your penis into your partner's vagina?"\] = "Yes") / (number of occasions where SEP Question 2 was answered "Yes" or "No").
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \["Were you satisfied with the hardness of your erection?"\] = "Yes") / (number of occasions where SEP Question 4 was answered "Yes" or "No").
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 4 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \["Were you satisfied with the hardness of your erection?"\] = "Yes") / (number of occasions where SEP Question 4 was answered "Yes" or "No").
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \["Were you satisfied with this sexual encounter?"\] = "Yes") / (number of occasions where SEP Question 5 was answered "Yes" or "No")
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 5 Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \["Were you satisfied with this sexual encounter?"\] = "Yes") / (number of occasions where SEP Question 5 was answered "Yes" or "No")
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
Time frame: Week 2, Week 4, and Week 6
Mean Per-Patient Percentage of 'Yes' Responses to Sexual Encounter Profile (SEP) Question 3 (Q3) Based on Attempts With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of Grade 1 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation- Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of Grade 2 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of Grade 3 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of Grade 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Baseline
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
Time frame: Week 2, Week 4 and Week 6
Mean Per-Patient Percentage of Grade 3 or 4 Events in Erection Hardness Grading Scale (EHGS) Based on Occasions With Sexual Stimulation - Change From Week 2
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
Time frame: Week 4 and Week 6
| Milestone | Open Label Sildenafil Citrate |
|---|---|
| Started | 117 |
| Completed | 110 |
| Not completed | 7 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 1 |
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 \& 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| International Index of Erectile Function (IIEF), Erectile Function (EF) Domain Score- Change From Baseline to Week 6 Last Observation Carried Forward (LOCF) | 10.96 ± 5.19 |
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 \& 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
| score on a scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 7.14 ± 5.21 |
| Week 4 (N=112) | 10.57 ± 5.43 |
| Week 6 (N=110) | 10.93 ± 5.26 |
| Week 6 Endpoint (N=112) | 10.95 ± 5.21 |
IIEF is a self-administered scale designed to assess erectile functioning: includes 15 questions on 5 relevant domains of male sexual function; one is erectile function (EF). IIEF-EF Domain: sum of scores for Questions 1, 2, 3, 4, 5 \& 15 from IIEF. Score range: 0 to 5 (Q1 to Q5), 1 to 5 (Q15); total 1 to 30. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 3.48 ± 3.97 |
| Week 6 (N=110) | 3.88 ± 4.38 |
| Week 6 LOCF (N=112) | 3.86 ± 4.35 |
| Week 6 Endpoint (N=112) | 3.86 ± 4.35 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 1.89 ± 2.40 |
| Week 4 (N=112) | 2.46 ± 2.32 |
| Week 6 (N=110) | 2.59 ± 2.44 |
| Week 6 LOCF (N=113) | 2.63 ± 2.45 |
| Week 6 Endpoint (N=112) | 2.59 ± 2.42 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is orgasmic function. IIEF Orgasmic Function Domain was sum of scores for Questions 9 and 10 from the IIEF. Score range: 0 to 5; total 0 to 10. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 0.61 ± 1.51 |
| Week 6 (N=110) | 0.75 ± 1.46 |
| Week 6 LOCF (N=112) | 0.74 ± 1.45 |
| Week 6 Endpoint (N=112) | 0.74 ± 1.45 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 1.43 ± 1.87 |
| Week 4 (N=112) | 2.00 ± 1.86 |
| Week 6 (N=110) | 2.25 ± 1.91 |
| Week 6 LOCF (N=113) | 2.26 ± 1.94 |
| Week 6 Endpoint (N=112) | 2.28 ± 1.93 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one of which is sexual desire. IIEF Sexual Desire Domain was sum of scores for Questions 11 and 12 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 0.55 ± 1.41 |
| Week 6 (N=110) | 0.81 ± 1.47 |
| Week 6 LOCF (N=112) | 0.83 ± 1.49 |
| Week 6 Endpoint (N=112) | 0.83 ± 1.49 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 3.18 ± 2.42 |
| Week 4 (N=112) | 4.38 ± 2.39 |
| Week 6 (N=110) | 4.73 ± 2.53 |
| Week 6 LOCF (N=113) | 4.70 ± 2.52 |
| Week 6 Endpoint (N=112) | 4.72 ± 2.52 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is intercourse satisfaction. IIEF Intercourse Satisfaction Domain: sum of scores for Questions 6, 7 and 8 from IIEF. Score range: 0 to 5; total 0 to 15. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 1.20 ± 2.10 |
| Week 6 (N=110) | 1.54 ± 2.20 |
| Week 6 LOCF (N=112) | 1.54 ± 2.19 |
| Week 6 Endpoint (N=112) | 1.54 ± 2.19 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 2.73 ± 2.38 |
| Week 4 (N=112) | 3.67 ± 2.49 |
| Week 6 (N=110) | 3.92 ± 2.52 |
| Week 6 LOCF (N=113) | 3.91 ± 2.53 |
| Week 6 Endpoint (N=112) | 3.89 ± 2.53 |
IIEF is a self-administered scale to assess erectile functioning. IIEF includes 15 questions and addresses the 5 relevant domains of male sexual function, one is overall satisfaction. IIEF Overall Satisfaction Domain was sum of scores for Questions 13 and 14 from the IIEF. Score range: 1 to 5; total 2 to 10. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 0.97 ± 1.88 |
| Week 6 (N=110) | 1.21 ± 1.92 |
| Week 6 LOCF (N=112) | 1.20 ± 1.90 |
| Week 6 Endpoint (N=112) | 1.20 ± 1.90 |
QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 32.71 ± 25.36 |
| Week 4 (N=112) | 46.21 ± 26.27 |
| Week 6 (N=110) | 45.53 ± 26.96 |
| Week 6 LOCF (N=113) | 45.28 ± 27.01 |
| Week 6 Endpoint (N=112) | 45.05 ± 27.02 |
QEQ is a self-administered scale used to assess erection hardness and overall quality of erections. The QEQ total score is defined as the sum of the scores from QEQ Questions 1-6. Score range: 1 to 5. Higher score indicates better outcome. Raw QEQ score ranges from 6-30 and is transformed onto a 0-100 scale.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 13.84 ± 21.10 |
| Week 6 (N=110) | 13.07 ± 24.25 |
| Week 6 LOCF (N=112) | 12.69 ± 24.26 |
| Week 6 Endpoint (N=112) | 12.69 ± 24.26 |
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 5.41 ± 4.40 |
| Week 4 (N=112) | 8.85 ± 4.96 |
| Week 6 (N=110) | 9.21 ± 5.19 |
| Week 6 LOCF (N=113) | 9.28 ± 5.14 |
| Week 6 Endpoint (N=112) | 9.25 ± 5.15 |
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Erection domain: sum of scores for Questions 1, 2, 3, 4, 5 and 6 from the Sex-Q. Score range: 1 to 5; total 6 to 30. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 3.51 ± 3.89 |
| Week 6 (N=110) | 3.91 ± 4.41 |
| Week 6 LOCF (N=112) | 3.91 ± 4.38 |
| Week 6 Endpoint (N=112) | 3.91 ± 4.38 |
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=113) | 6.68 ± 4.86 |
| Week 4 (N=112) | 9.94 ± 5.21 |
| Week 6 (N=108) | 10.59 ± 5.08 |
| Week 6 LOCF (N=111) | 10.63 ± 5.03 |
| Week 6 Endpoint (N=110) | 10.64 ± 5.06 |
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions (q). Sex-Q Satisfaction domain:sum of scores for q 10, 11, 12, 13, 14 and 15 from Sex-Q. Score range:1 to 5; total 6 to 30. Higher score indicates better outcome
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 3.29 ± 4.10 |
| Week 6 (N=108) | 4.03 ± 5.09 |
| Week 6 LOCF (N=110) | 4.01 ± 5.04 |
| Week 6 Endpoint (N=110) | 4.01 ± 5.04 |
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=112) | 2.79 ± 2.44 |
| Week 4 (N=111) | 4.23 ± 2.56 |
| Week 6 (N=108) | 4.74 ± 2.84 |
| Week 6 LOCF (N=111) | 4.78 ± 2.81 |
| Week 6 Endpoint (N=110) | 4.76 ± 2.82 |
Sexual Experience Questionnaire (Sex-Q) is a self-administered questionnaire designed to assess functional, emotional, and social aspects of sexual experience. Sex-Q includes 15 questions. Sex-Q Relationship domain was sum of scores for Questions 7, 8 and 9 from the Sex-Q. Score range: 1 to 5; total 3 to 15. Higher score indicates better outcome.
| score on scale | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=112) | 1.49 ± 1.91 |
| Week 6 (N=109) | 1.96 ± 2.08 |
| Week 6 LOCF (N=111) | 1.98 ± 2.07 |
| Week 6 Endpoint (N=111) | 1.98 ± 2.07 |
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 1 (Week 2) N=110 | 8.84 ± 28.70 |
| Question 1 (Week 4) N=108 | 10.18 ± 27.51 |
| Question 1 (Week 6) N=105 | 12.29 ± 28.88 |
| Question 1 (Week 6 LOCF) N=110 | 11.96 ± 28.33 |
| Question 1 (Week 6 Endpoint) N=108 | 11.95 ± 28.55 |
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to Question 1 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 1 \[Were you able to achieve at least some erection (some enlargement of the penis)?\] = Yes) / (number of occasions where Question 1 was answered Yes or No)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 1 (Week 4) N=111 | 1.37 ± 14.85 |
| Question 1 (Week 6) N=108 | 3.12 ± 14.26 |
| Question 1 (Week 6 LOCF) N=113 | 2.98 ± 13.95 |
| Question 1 (Week 6 Endpoint) N=111 | 3.04 ± 14.07 |
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \["Were you able to insert your penis into your partner's vagina?"\] = "Yes") / (number of occasions where SEP Question 2 was answered "Yes" or "No").
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 2 (Week 2) N=102 | 15.37 ± 30.51 |
| Question 2 (Week 4) N=100 | 17.15 ± 32.22 |
| Question 2 (Week 6) N=97 | 18.22 ± 32.44 |
| Question 2 (Week 6 LOCF) N=102 | 17.33 ± 31.87 |
| Question 2 (Week 6 Endpoint) N=100 | 17.68 ± 32.10 |
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 2 \["Were you able to insert your penis into your partner's vagina?"\] = "Yes") / (number of occasions where SEP Question 2 was answered "Yes" or "No").
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 2 (Week 4) N=110 | 1.46 ± 9.41 |
| Question 2 (Week 6) N=107 | 1.18 ± 12.33 |
| Question 2 (Week 6 LOCF) N=112 | 1.13 ± 12.05 |
| Question 2 (Week 6 Endpoint) N=110 | 1.15 ± 12.16 |
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 3 (Week 2) N=102 | 56.96 ± 38.93 |
| Question 3 (Week 4) N=100 | 70.78 ± 35.46 |
| Question 3 (Week 6) N=97 | 71.23 ± 35.79 |
| Question 3 (Week 6 LOCF) N=102 | 72.15 ± 35.41 |
| Question 3 (Week 6 Endpoint) N=100 | 71.60 ± 35.55 |
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 2 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes) / (number of occasions where SEP Question 3 was answered Yes or No)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 3 (Week 4) N=110 | 13.56 ± 30.89 |
| Question 3 (Week 6) N=107 | 14.25 ± 31.31 |
| Question 3 (Week 6 LOCF) N=112 | 14.51 ± 31.77 |
| Question 3 (Week 6 Endpoint) N=110 | 14.77 ± 32.00 |
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \["Were you satisfied with the hardness of your erection?"\] = "Yes") / (number of occasions where SEP Question 4 was answered "Yes" or "No").
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 4 (Week 2) N=102 | 58.58 ± 41.24 |
| Question 4 (Week 4) N=100 | 76.29 ± 37.21 |
| Question 4(Week 6) N=97 | 77.69 ± 37.26 |
| Question 4 (Week 6 LOCF) N=102 | 78.79 ± 36.65 |
| Question 4 (Week 6 Endpoint) N=100 | 78.36 ± 36.89 |
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 4 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 4 \["Were you satisfied with the hardness of your erection?"\] = "Yes") / (number of occasions where SEP Question 4 was answered "Yes" or "No").
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 4 (Week 4) N=110 | 17.90 ± 36.63 |
| Question 4 (Week 6) N=107 | 19.50 ± 36.84 |
| Question 4 (Week 6 LOCF) N=112 | 19.52 ± 36.99 |
| Question 4 (Week 6 Endpoint) N=110 | 19.88 ± 37.23 |
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \["Were you satisfied with this sexual encounter?"\] = "Yes") / (number of occasions where SEP Question 5 was answered "Yes" or "No")
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 5 (Week 2) N=101 | 57.34 ± 42.60 |
| Question 5 (Week 4) N=100 | 70.72 ± 40.30 |
| Question 5 (Week 6) N=97 | 70.63 ± 40.78 |
| Question 5 (Week 6 LOCF) N=102 | 72.07 ± 40.27 |
| Question 5 (Week 6 Endpoint) N=100 | 71.51 ± 40.48 |
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Question 5 based on occasions (= sexual stimulation): 100\*(number of occasions where SEP Question 5 \["Were you satisfied with this sexual encounter?"\] = "Yes") / (number of occasions where SEP Question 5 was answered "Yes" or "No")
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Question 5 (Week 4) N=109 | 13.10 ± 29.11 |
| Question 5 (Week 6) N=106 | 14.11 ± 32.53 |
| Question 5 (Week 6 LOCF) N=111 | 13.47 ± 31.92 |
| Question 5 (Week 6 Endpoint) N=109 | 13.72 ± 32.16 |
Mean change: mean change at each visit minus mean at baseline. Percent of "Yes" responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Week 2 (N=102) | 56.96 ± 38.93 |
| Week 4 (N=100) | 70.78 ± 35.46 |
| Week 6 (N=97) | 71.23 ± 35.79 |
| Week 6 LOCF (N=102) | 72.15 ± 35.41 |
| Week 6 Endpoint (N=100) | 71.60 ± 35.55 |
Mean change: mean change at each visit minus mean at Week 2. Percent of "Yes" responses to SEP Q3 based on attempts with sexual stimulation (SS): 100\* (number of attempts with SS where SEP Q3 \[Did your erection last long enough for you to have successful intercourse?\] = Yes)/(number of attempts with SS where SEP Q3 was answered Yes or No)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Week 4 (N=110) | 13.56 ± 30.89 |
| Week 6 (N=107) | 14.25 ± 31.31 |
| Week 6 LOCF (N=112) | 14.51 ± 31.77 |
| Week 6 Endpoint (N=110) | 14.77 ± 32.00 |
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 1 (Week 2) N=103 | -12.58 ± 37.77 |
| Grade 1 (Week 4) N=101 | -20.55 ± 35.04 |
| Grade 1 (Week 6) N=98 | -22.53 ± 36.64 |
| Grade 1 (Week 6 LOCF) N=103 | -21.44 ± 36.06 |
| Grade 1 (Week 6 Endpoint) N=101 | -21.86 ± 36.29 |
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 1 (1=increase in size, but not hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 1)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 1 (Week 4) N=110 | -6.79 ± 22.58 |
| Grade 1 (Week 6) N=107 | -6.85 ± 23.02 |
| Grade 1 (Week 6 LOCF) N=112 | -7.43 ± 24.20 |
| Grade 1 (Week 6 Endpoint) N=110 | -7.57 ± 24.40 |
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
| Per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 2 (Week 2) N=103 | -9.87 ± 34.44 |
| Grade 2 (Week 4) N=101 | -11.74 ± 32.80 |
| Grade 2 (Week 6) N=98 | -12.78 ± 33.56 |
| Grade 2 (Week 6 LOCF) N=103 | -13.13 ± 33.94 |
| Grade 2 (Week 6 Endpoint) N=101 | -12.40 ± 33.13 |
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 2 (2= hard, but not hard enough for penetration) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 2)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 2 (Week 4) N=110 | -2.39 ± 22.00 |
| Grade 2 (Week 6) N=107 | -1.91 ± 20.73 |
| Grade 2 (Week 6 LOCF) N=112 | -2.71 ± 22.28 |
| Grade 2 (Week 6 Endpoint) N=110 | -2.76 ± 22.48 |
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 3 (Week 2) N=103 | -10.82 ± 56.75 |
| Grade 3 (Week 4) N=101 | -29.16 ± 59.81 |
| Grade 3 (Week 6) N=98 | -30.79 ± 60.90 |
| Grade 3 (Week 6 LOCF) N=103 | -30.27 ± 61.70 |
| Grade 3 (Week 6 Endpoint) N=101 | -30.87 ± 60.54 |
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (3= hard enough for penetration \[but not completely hard\]) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 1 (Week 4) N=110 | -18.36 ± 46.03 |
| Grade 1 (Week 6) N=107 | -22.16 ± 45.24 |
| Grade 1 (Week 6 LOCF) N=112 | -20.28 ± 45.86 |
| Grade 1 (Week 6 Endpoint) N=110 | -20.65 ± 46.20 |
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 4 (Week 2) N=103 | 33.27 ± 41.43 |
| Grade 4 (Week 4) N=101 | 61.45 ± 44.77 |
| Grade 4 (Week 6) N=98 | 66.10 ± 45.15 |
| Grade 4 (Week 6 LOCF) N=103 | 64.84 ± 45.70 |
| Grade 4 (Week 6 Endpoint) N=101 | 65.13 ± 45.56 |
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 4 (4= completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 4)/(number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 4 (Week 4) N=110 | 27.53 ± 40.19 |
| Grade 4 (Week 6) N=107 | 30.92 ± 41.90 |
| Grade 4 (Week 6 LOCF) N=112 | 30.43 ± 41.88 |
| Grade 4 (Week 6 Endpoint) N=110 | 30.98 ± 42.06 |
Mean change: mean change at each visit minus mean at baseline. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 3 or 4 (Week 2) N=103 | 22.45 ± 46.10 |
| Grade 3 or 4 (Week 4) N=101 | 32.30 ± 42.15 |
| Grade 3 or 4 (Week 6) N=98 | 35.31 ± 43.52 |
| Grade 3 or 4 (Week 6 LOCF) N=103 | 34.57 ± 43.48 |
| Grade 3 or 4 (Week 6 Endpoint) N=101 | 34.26 ± 43.29 |
Mean change: mean change at each visit minus mean at Week 2. Percent of Grade 3 (hard enough for penetration \[but not completely hard\]) or 4 (completely hard) erection hardness based on occasions: 100\*(number of occasions where Erection Hardness Scale Answer 3 or 4)/ (number of occasions where Erection Hardness Scale was answered)
| per-patient percentage | Open Label Sildenafil Citrate |
|---|---|
| Grade 3 or 4 (Week 4) N=110 | 9.18 ± 29.45 |
| Grade 3 or 4 (Week 6) N=107 | 8.75 ± 29.26 |
| Grade 3 or 4 (Week 6 LOCF ) N=112 | 10.15 ± 31.11 |
| Grade 3 or 4 (Week 6 Endpoint ) N=110 | 10.33 ± 31.36 |
Non-serious events are listed at a 1.70% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open Label Sildenafil Citrate | — | 0/117 (0%) | — |
| Event | Open Label Sildenafil Citrate |
|---|---|
| HeadacheNervous system disorders | 18/117 |
| Hot FlushVascular disorders | 10/117 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 3/117 |
| FlushingVascular disorders | 3/117 |
| GastritisGastrointestinal disorders | 3/117 |
| Age, Continuous(years) | Open Label Sildenafil Citrate |
|---|---|
| Mean | 53.3 ± 11 |
| Sex: Female, Male(Participants) | Open Label Sildenafil Citrate |
|---|---|
| Female | 0 |
| Male | 117 |
The record gives a start of Jun 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →